Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

VTRS – Viatris Inc.

Viatris Inc.
VTRS
$20.85
Name : Viatris Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $23,903,582,208.00
EPSttm : -0.53
finviz dynamic chart for VTRS
Viatris Inc.
$20.85
1.76%
$0.36
VTRS — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

3.38

Margin Of Safety %

19

Put/Call OI Ratio

0.27

EPS Next Q Diff

-0.08

EPS Last/This Y

0.24

EPS This/Next Y

0.16

Price

20.86

Target Price

21.33

Analyst Recom

2.21

Performance Q

29.5

Upside

-155.9%

Beta

0.86

Ticker: VTRS




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-10-12VTRS17.550.280.11124048
2026-10-13VTRS17.250.280.18123857
2026-10-14VTRS17.450.281.20124077
2026-10-15VTRS18.220.280.19124166
2026-10-16VTRS18.650.280.03125197
2026-10-19VTRS18.260.270.27110618
2026-10-20VTRS18.660.271.22111027
2026-10-21VTRS18.450.280.13111736
2026-10-22VTRS18.480.280.08111883
2026-10-23VTRS180.270.03113463
2026-10-26VTRS18.30.270.33117045
2026-10-27VTRS18.730.270.21118327
2026-10-28VTRS18.770.270.08118994
2026-10-29VTRS19.220.271.01119152
2026-10-30VTRS19.030.270.57119903
2026-11-02VTRS18.670.270.14120090
2026-11-03VTRS18.940.271.00120254
2026-11-04VTRS19.250.2712.92120490
2026-11-05VTRS18.920.260.31119748
2026-11-06VTRS19.740.260.28119561
2026-11-09VTRS20.50.260.25120968
2026-11-10VTRS20.860.270.11121848
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-10-12VTRS17.56-4.0644.92.52
2026-10-13VTRS17.22-3.7640.52.52
2026-10-14VTRS17.46-3.7649.82.52
2026-10-15VTRS18.22-4.0662.52.52
2026-10-16VTRS18.66-3.9653.32.52
2026-10-19VTRS18.26-3.9639.92.52
2026-10-20VTRS18.26-3.9639.92.52
2026-10-21VTRS18.65-3.9652.62.52
2026-10-22VTRS18.48-3.9646.62.52
2026-10-23VTRS17.99-3.9638.42.52
2026-10-26VTRS18.30-4.3651.22.52
2026-10-27VTRS18.73-4.3653.32.52
2026-10-28VTRS18.77-4.3646.92.52
2026-10-29VTRS19.22-4.3653.32.52
2026-10-30VTRS19.03-4.3643.32.52
2026-11-02VTRS18.68-4.8640.62.51
2026-11-04VTRS19.25-4.8651.32.51
2026-11-05VTRS18.97-4.8641.82.51
2026-11-06VTRS19.974.1533.52.51
2026-11-09VTRS20.504.1526.42.51
2026-11-10VTRS20.866.4523.12.59
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-10-12VTRS-0.21-0.033.74
2026-10-13VTRS-0.21-0.033.74
2026-10-14VTRS-0.21-0.033.74
2026-10-15VTRS-0.21-0.033.74
2026-10-16VTRS-0.21-0.033.74
2026-10-19VTRS-0.21-0.083.74
2026-10-20VTRS-0.21-0.083.74
2026-10-21VTRS-0.21-0.083.74
2026-10-22VTRS-0.21-0.083.74
2026-10-23VTRS-0.21-0.083.74
2026-10-26VTRS-0.21-0.203.74
2026-10-27VTRS-0.21-0.203.37
2026-10-28VTRS-0.21-0.203.37
2026-10-29VTRS-0.21-0.203.37
2026-10-30VTRS-0.21-0.203.37
2026-11-02VTRS-0.21-0.233.37
2026-11-03VTRS-0.21-0.233.37
2026-11-05VTRS-0.21-0.233.37
2026-11-06VTRS-0.21-0.233.37
2026-11-09VTRS-0.21-0.213.38
2026-11-10VTRS-0.21-0.213.38
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

0.71

Avg. EPS Est. Current Quarter

0.61

Avg. EPS Est. Next Quarter

0.63

Insider Transactions

-0.21

Institutional Transactions

-0.21

Beta

0.86

Average Sales Estimate Current Quarter

3761

Average Sales Estimate Next Quarter

3585

Fair Value

24.8

Quality Score

48

Growth Score

45

Sentiment Score

94

Actual DrawDown %

-1.6

Max Drawdown 5-Year %

-45.7

Target Price

21.33

P/E

Forward P/E

7.58

PEG

0.93

P/S

1.62

P/B

1.75

P/Free Cash Flow

11.33

EPS

-0.53

Average EPS Est. Cur. Y​

2.59

EPS Next Y. (Est.)

2.75

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

-4.12

Relative Volume

1.25

Return on Equity vs Sector %

-30.7

Return on Equity vs Industry %

-11.1

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.07

EBIT Estimation

523.1
◆ VTRS Healthcare
$20.85
📉
Swing / Pullback
Buy the dip on strong trends
47 /100
WEAK
Trend
20/20
Pullback
6/25
Volume
1/15
Valuation
9/20
TP/AR
4/10
Options
7/10
RSI
74.2
Range 1M
97.4%
Sup Dist
3.7%
🚀
Momentum Growth
Ride accelerating trends
54 /100
WEAK
Momentum
24/25
Growth
8/30
Estimates
6/20
Inst/Vol
6/15
Options
10/10
EPS Yr
9.1%
EPS NY
7.2%
52W%
99.1%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +101.2% upside
Quality
7/30
Valuation
23/30
Growth
8/25
Stability
4/10
LT Trend
4/5
Upside
+101.2%
Quality
48
MoS
19%
VTRS — P/E HistoricalDrug Manufacturers - Specialty & Generic
Viatris Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 30000
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
VTRS

Latest News

—
Caricamento notizie per VTRS…
stock quote shares VTRS – Viatris Inc. Stock Price stock today
news today VTRS – Viatris Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VTRS – Viatris Inc. yahoo finance google finance
stock history VTRS – Viatris Inc. invest stock market
stock prices VTRS premarket after hours
ticker VTRS fair value insiders trading